Therapy-induced tumour secretomes promote resistance and tumour progression

Anna C. Obenauf, Yilong Zou, Andrew L. Ji, Sakari Vanharanta, Weiping Shu, Hubing Shi, Xiangju Kong, Marcus C. Bosenberg, Thomas Wiesner, Neal Rosen, Roger S. Lo, Joan Massagué

Research output: Contribution to journalArticlepeer-review

325 Scopus citations

Abstract

Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer. Here we show that targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted signals in drug-stressed human and mouse melanoma and human lung adenocarcinoma cells. This therapy-induced secretome stimulates the outgrowth, dissemination and metastasis of drug-resistant cancer cell clones and supports the survival of drug-sensitive cancer cells, contributing to incomplete tumour regression. The tumour-promoting secretome of melanoma cells treated with the kinase inhibitor vemurafenib is driven by downregulation of the transcription factor FRA1. In situ transcriptome analysis of drug-resistant melanoma cells responding to the regressing tumour microenvironment revealed hyperactivation of several signalling pathways, most prominently the AKT pathway. Dual inhibition of RAF and the PI(3)K/AKT/mTOR intracellular signalling pathways blunted the outgrowth of the drug-resistant cell population in BRAF mutant human melanoma, suggesting this combination therapy as a strategy against tumour relapse. Thus, therapeutic inhibition of oncogenic drivers induces vast secretome changes in drug-sensitive cancer cells, paradoxically establishing a tumour microenvironment that supports the expansion of drug-resistant clones, but is susceptible to combination therapy.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalNature
Volume520
Issue number7547
DOIs
StatePublished - 15 Apr 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Therapy-induced tumour secretomes promote resistance and tumour progression'. Together they form a unique fingerprint.

Cite this